In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline
- PMID: 34550726
- PMCID: PMC8641759
- DOI: 10.1126/scitranslmed.abj2511
In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline
Abstract
Several autopsy studies recognize the locus coeruleus (LC) as the initial site of hyperphosphorylated TAU aggregation, and as the number of LC neurons harboring TAU increases, TAU pathology emerges throughout the cortex. By conjointly using dedicated MRI measures of LC integrity and TAU and amyloid PET imaging, we aimed to address the question whether in vivo LC measures relate to initial cortical patterns of Alzheimer’s disease (AD) fibrillar proteinopathies or cognitive dysfunction in 174 cognitively unimpaired and impaired older individuals with longitudinal cognitive measures. To guide our interpretations, we verified these associations in autopsy data from 1524 Religious Orders Study and Rush Memory and Aging Project and 2145 National Alzheimer’s Coordinating Center cases providing three different LC measures (pigmentation, tangle density, and neuronal density), Braak staging, β-amyloid, and longitudinal cognitive measures. Lower LC integrity was associated with elevated TAU deposition in the entorhinal cortex among unimpaired individuals consistent with postmortem correlations between LC tangle density and successive Braak staging. LC pigmentation ratings correlated with LC neuronal density but not with LC tangle density and were particularly worse at advanced Braak stages. In the context of elevated β-amyloid, lower LC integrity and greater cortical tangle density were associated with greater TAU burden beyond the medial temporal lobe and retrospective memory decline. These findings support neuropathologic data in which early LC TAU accumulation relates to disease progression and identify LC integrity as a promising indicator of initial AD-related processes and subtle changes in cognitive trajectories of preclinical AD.
Conflict of interest statement
Competing interests
HIJ received funding from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant agreement [IF-2015-GF, 706714]. KVP has served as a paid consultant for Biogen. DMR has done consulting for Eli Lilly, Biogen Idec and Digital Cognition Technologys and served on the Scientific Advisory Board for Neurotrack. KAJ has served as paid consultant for Janssen, Novartis, Biogen, Roche, Lundberg, and Abbvie. He is a site co-investigator for Lilly/Avid and Janssen, and receives research support for clinical trials from Eisai, Lilly, and Cerveau. RAS has served as a paid consultant for Ionis, Shionogi, Biogen, Genentech, Oligomerix, Cytox, Acumen, JOMDD, Renew, Neuraly, AC Immune, Alnylam, Janssen, Neurocentria, Prothena, Eisai, Takeda and Roche and receives research support for clinical trials from Eisai, Eli Lilly, NIA and Alzheimer’s Association. DAB was on a DSMB for AbbVie, an adjudication committee for Takeda, a SBIR consultant for Origent, and he has funding from Neurovision to perform eye amyloid imaging. JCP also holds an adjunct professor position at the University of Pittsburgh. These relationships are not related to the content in the manuscript. All other authors report no relevant conflicts.
Figures







References
-
- Braak H, Braak E, Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica 82, 239–259 (1991). - PubMed
-
- Braak H, Thal DR, Ghebremedhin E, Del Tredici K, Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70, 960–969 (2011). - PubMed
-
- Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG, Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71, 362–381 (2012). - PMC - PubMed
-
- Braak H, Del Tredici K, The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta neuropathologica 121, 171–181 (2011). - PubMed
-
- Ehrenberg AJ, Nguy AK, Theofilas P, Dunlop S, Suemoto CK, Di Lorenzo Alho AT, Leite RP, Diehl Rodriguez R, Mejia MB, Rub U, Farfel JM, de Lucena Ferretti-Rebustini RE, Nascimento CF, Nitrini R, Pasquallucci CA, Jacob-Filho W, Miller B, Seeley WW, Heinsen H, Grinberg LT, Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer’s disease. Neuropathol Appl Neurobiol 43, 393–408 (2017). - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- P50 AG005142/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- R01 AG050436/AG/NIA NIH HHS/United States
- P50 AG047266/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- R01 AG052414/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- P30 AG072977/AG/NIA NIH HHS/United States
- P50 AG047366/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- S10 RR023043/RR/NCRR NIH HHS/United States
- R01 AG046396/AG/NIA NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- P30 AG053760/AG/NIA NIH HHS/United States
- P30 AG066444/AG/NIA NIH HHS/United States
- P41 EB022544/EB/NIBIB NIH HHS/United States
- P30 AG062428/AG/NIA NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- U01 AG032984/AG/NIA NIH HHS/United States
- S10 RR021110/RR/NCRR NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- P01 AG036694/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- S10 RR019307/RR/NCRR NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- R01 AG017917/AG/NIA NIH HHS/United States
- P50 AG047270/AG/NIA NIH HHS/United States
- P30 AG072980/AG/NIA NIH HHS/United States
- P30 AG062429/AG/NIA NIH HHS/United States
- S10 OD018035/OD/NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG049638/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P30 AG062422/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P30 AG066509/AG/NIA NIH HHS/United States
- S10 OD010364/OD/NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P30 AG062715/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- T32 EB013180/EB/NIBIB NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- R01 AG062559/AG/NIA NIH HHS/United States
- S10 RR023401/RR/NCRR NIH HHS/United States
- R01 AG015819/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical